Retatrutide side effects reported so far have most often involved the gastrointestinal system. Phase 2 and Phase 3 studies have reported nausea, diarrhea, constipation and vomiting. Newer Phase 3 publications also provide information from larger and more varied study populations.
Quick answer: The most frequently reported retatrutide side effects in published trials are gastrointestinal events, especially nausea, diarrhea, constipation and vomiting. Retatrutide remains investigational and has not been approved by the FDA as of November 17, 2026.
What did the retatrutide trials report?
Clinical evidence for retatrutide includes Phase 2 and Phase 3 randomized trials. Retatrutide is a triple-receptor agonist that acts on glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors. It remains an investigational compound (Jastreboff et al., 2023; Lilly, retatrutide overview, updated October 2026).
The 2023 Phase 2 obesity trial enrolled adults with obesity. Treatment-emergent adverse events were reported in 70% of placebo participants and 73% to 94% of participants across retatrutide groups. The most frequently reported events were gastrointestinal, including nausea, diarrhea, vomiting and constipation. The publication reported discontinuation because of adverse events in 6% to 16% of participants in retatrutide groups, compared with none in the placebo group. These findings came from a Phase 2 trial and should be read in that context (Jastreboff et al., 2023; ClinicalTrials.gov, NCT04881760).
The evidence base expanded in 2026. The Phase 3 TRIUMPH-1 trial studied adults with obesity without type 2 diabetes. It randomized 2,339 participants and followed outcomes over 80 weeks. The journal publication identified gastrointestinal events as the most common adverse events (Jastreboff et al., 2026; ClinicalTrials.gov, NCT05929066).
What are the most common retatrutide side effects?
The TRIUMPH-1 safety results reported nausea, diarrhea, constipation and vomiting more frequently in retatrutide groups than in the placebo group. The trial report and associated clinical results provide these ranges across treatment groups (Jastreboff et al., 2026; TRIUMPH-1 safety results).
What are the most common retatrutide side effects
| Adverse event | Retatrutide groups | Placebo |
|---|---|---|
| Nausea | 29%–42% | 15% |
| Diarrhea | 25%–34% | 13% |
| Constipation | 24%–26% | 11% |
| Vomiting | 11%–25% | 5% |
| Dysesthesia | 5%–13% | 1% |
| Urinary tract infection | 8%–9% | 5% |
| Discontinuation due to adverse events | 4%–11% | 5% |
These figures describe the trial population and its reporting definitions. They do not predict an individual outcome. Dysesthesia refers to an abnormal sensation, such as tingling or altered skin sensation. The TRIUMPH-1 clinical materials described dysesthesia and urinary tract infections as generally mild to moderate. The majority resolved during the trial, and most participants continued treatment (TRIUMPH-1 safety results).
What did Phase 3 research report in participants with type 2 diabetes?
The Phase 3 TRIUMPH-2 trial studied adults with obesity or overweight and type 2 diabetes. It randomized 1,152 participants. The most frequently reported adverse events were gastrointestinal. These included diarrhea, nausea, constipation and vomiting (Bellido et al., 2026; ClinicalTrials.gov, NCT05929079).
What did Phase 3 research report in participants with type 2 diabetes
| Adverse event | Retatrutide groups | Placebo |
|---|---|---|
| Diarrhea | 27%–34% | 13% |
| Nausea | 14%–28% | 8% |
| Constipation | 14%–17% | 9% |
| Vomiting | 6%–16% | 4% |
| Dysesthesia | 4%–7% | 1% |
| Discontinuation due to adverse events | 4%–12% | 5% |
The published TRIUMPH-2 abstract reported that the gastrointestinal events were more common in retatrutide groups than placebo. It also reported more hypotension and dysesthesia in some retatrutide groups. Trial investigators considered the deaths during the study unrelated to the study intervention. That assessment is a trial finding, not a general statement about all possible retatrutide exposures (Bellido et al., 2026).
Another Phase 3 study, TRANSCEND-T2D-1, evaluated adults with type 2 diabetes whose glycemic control was inadequate with diet and exercise alone. It randomized 537 participants. The Lancet report described the most frequent adverse events as generally mild-to-moderate gastrointestinal events that subsided over time. Treatment discontinuations due to adverse events were reported in 2% to 5% of retatrutide participants and none of the placebo participants. The report recorded no severe hypoglycemia (Bajaj et al., 202600967-0)).
Is retatrutide FDA approved?
No. As of November 17, 2026, retatrutide remains an investigational medicine and has not been approved by the FDA. The developer's October 2026 information page states that it is not on the market and remains under evaluation in Phase 3 studies (Lilly, updated October 2026).
The developer has reported Phase 3 findings from several TRIUMPH and TRANSCEND studies. It plans to submit a Biologics License Application in the first quarter of 2027. That is a planned submission, not an FDA approval or a guarantee (Lilly, TRIUMPH-2 results, 2026; Lilly, consumer-market status).
The distinction between investigational clinical-trial material and products marketed outside authorized channels is important. The FDA warns that unapproved GLP-1 drug products do not undergo its premarket review for safety, effectiveness and quality. Lilly separately warns that purported unapproved retatrutide products may contain incorrect ingredients, contaminants or impurities. These warnings concern unapproved products and do not establish the analytical status of any particular research lot (FDA, unapproved GLP-1 drugs; Lilly, retatrutide overview).
How should the current evidence be interpreted?
The Phase 3 evidence is more informative than the original Phase 2 trial because it includes larger participant groups and different clinical populations. The results nevertheless remain limited to the populations, study periods and monitoring frameworks reported by the investigators. They do not establish long-term outcomes beyond the follow-up completed in each trial.
The most consistent reported pattern across the studies is gastrointestinal adverse events. TRIUMPH-1 also reported dysesthesia and urinary tract infections more frequently in some retatrutide groups. TRIUMPH-2 reported hypotension and dysesthesia as additional events of interest. The frequency and mix of adverse events differed between trials and study populations (Jastreboff et al., 2023; Jastreboff et al., 2026; Bellido et al., 2026).
There is no FDA-approved retatrutide prescribing label. Accordingly, safety information should be attributed to the trial reports rather than presented as established label information. Regulatory status can change, so this article identifies its review date and links to the developer's current status notice.
Frequently asked questions
What are the most common retatrutide side effects?
The Phase 2 and Phase 3 trials most often reported nausea, diarrhea, constipation and vomiting. Reported rates varied across trials and treatment groups.
Is retatrutide FDA approved?
No. The developer described retatrutide as investigational in October 2026. It stated that it plans to submit an application in the first quarter of 2027.
What is dysesthesia in retatrutide trials?
Dysesthesia is an abnormal sensation. TRIUMPH-1 and TRIUMPH-2 reported it more frequently in some retatrutide groups than in placebo groups.
Did the Phase 3 trials report serious adverse events?
Yes. TRIUMPH-1 and TRIUMPH-2 reported serious adverse events. Their rates and types varied by trial group and participant population. The trial reports should be consulted for the complete safety tables.
Are retatrutide side effects fully known?
No. Retatrutide remains investigational. The available results describe the participants and follow-up periods studied so far, not every possible long-term outcome.
What to know now
- The most frequently reported events across retatrutide trials have been gastrointestinal.
- Phase 3 publications from 2026 add evidence from participants with obesity, with and without type 2 diabetes.
- Retatrutide remains investigational and is not FDA approved as of November 17, 2026.
What we’re watching
- The developer has stated that it plans to submit a Biologics License Application in the first quarter of 2027. The submission and any later FDA action remain future events.
- Further publications from the TRIUMPH and TRANSCEND programs may add longer-term safety information and results from additional study populations.
Vitrapep research material
Vitrapep sells retatrutide for laboratory research use only. It is not for human or veterinary use. Related site information appears in the retatrutide research guide and where-to-buy information.

Retatrutide
Specifications for the retatrutide sold for laboratory research. COA available with each lot.